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Introduction. Pneumonia remains a common reason for hospital-
izing infants and the elderly worldwide, and streptococcal infec-
tion is often responsible. The aim of this study was to assess the 
burden of pneumonia in a large general population.
Methods. All pneumonia-related hospitalizations from 2004 to 
2013 in north-east Italy were identified from the hospital records 
with a first-listed diagnosis on discharge of bacterial pneumonia, 
or a first-listed diagnosis on discharge of meningitis, septicemia 
or empyema associated with a secondary diagnosis of bacterial 
pneumonia. We identified major comorbidities, calculated age-
specific case-fatality rates (CFR), and estimated the related cost 
to the health care system.
Results. Of the 125,722 hospitalizations identified, 96.9% were 
cases of pneumonia, 2.4% of septicemia, 0.4% of meningitis, and 
0.3% of empyema; 75.3% of hospitalizations involved ≥ 65-year-
olds. The overall CFR was 12.4%, and it increased with age, 
peaking in people over 80 (19.6%).
The mean annual pneumonia-associated hospitalization rate was 
204.6 per 100,000 population, and it peaked in 0- to 4-year-old chil-
dren (325.6 per 100,000 in males, 288.9 per 100,000 in females), 
and adults over 65 (844.9 per 100,000 in males, 605.7 per 100,000 
in females).
Hospitalization rates dropped over the years for the 0-4 year-olds, 
and rose for people over 80. The estimated overall annual cost of 
these pneumonia-related hospitalizations was approximately € 41 
million.
Conclusions. This study shows that the burden on resources for 
pneumonia-related hospitalization is an important public health 
issue. Prevention remains the most valuable tool for containing pneu-
monia, and vaccination strategies can help in the primary prevention 
of infection, possibly reducing the number of cases in all age groups.
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Summary
Introduction
Pneumonia remains a common reason for the hospitali-
zation of infants and elderly  adults  [1-3]. The disease 
can be caused by a variety of micro-organisms, but the 
pathogen most often responsible for pneumonia is the 
bacterium Streptococcus pneumoniae, especially in in-
dustrialized countries [4, 5].
Pneumonia pathogens may be reported in different ways, 
depending on the capabilities of in-hospital laboratories, 
how studies on them are designed, and the season or re-
gion in which studies are conducted [6]. They can cause 
a spectrum of diseases of variable severity and, when 
the organism invades normally sterile sites such as the 
bloodstream and meninges, the resulting forms are clas-
sified as invasive pneumococcal disease (IPD) [1].
Pneumococcal infections in adults can be a cause of 
community-acquired pneumonia (CAP), a respiratory 
disease with a high prevalence in the general population, 
a marked clinical heterogeneity, and a variable sever-
ity [2]. CAP remains a leading cause of morbidity and 
about 30% of CAP patients require hospitalization. 
The introduction of a 7-valent pneumococcal conjugate 
vaccine (PCV7) that targets seven serotypes (4, 6B, 9V, 
14, 18C, 19F and 23F) as part of children’s national im-
munization programs has led to a reduction in the hospi-
tal admission rates for all-cause pneumonia, particularly 
among children. A herd effect has also been reported in 
some countries [7-10].
The arrival on the market of more valent conjugate vac-
cines (10-valent and 13-valent) and the availability of 
13-valent pneumococcal conjugate vaccine (PCV13) for 
adults, offers new opportunities to prevent the diseases 
caused by S. pneumoniae [11].
An immunization program based on a 7-valent pneu-
mococcal conjugate vaccine (PCV7) was first in-
troduced in the Veneto and Friuli Venezia Giulia 
regions of north-east Italy in the early 2000s as an 
optional vaccination only for infants at risk (at 2-3 
and 14  months old). The program was subsequently 
extended to offer vaccination to all children in the 
Veneto and Friuli Venezia Giulia regions in 2005 
and 2009, respectively. In 2010, PCV13 was adopted 
in both regions instead of the PCV7 vaccine, and a 
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catch-up program was implemented for infants up to 
36 months old. 
The present study investigated the pneumonia potential-
ly preventable by vaccination, considering hospitaliza-
tion for pneumonia and for meningitis, septicemia and 
empyema associated with pneumonia. We estimated: i) 
the pneumonia-related hospitalization (PRH) rate; ii) the 
age-specific case-fatality rate (CFR); iii) the trends of 
the PRH rates by PCV7 or PCV13 vaccination period for 
each region; and iv) the economic cost of PRH.
Methods
Setting and data source
We conducted this retrospective study in the Veneto and 
Friuli Venezia Giulia regions, which have populations 
of 4.9 and 1.2 million, respectively. We analyzed the 
hospital discharge records (HDRs) of public and accred-
ited private hospitals in the two regions from 1 January 
2004 to 31 December 2013. HDRs include the follow-
ing data: details of the hospital; patient’s name, date of 
birth, gender, place of residence, and date of admission; 
surgical and other procedures; and date and type of dis-
charge. Each HDR contained one primary diagnosis (or 
first-listed diagnosis) and up to five secondary diagnoses 
based on the diagnostic codes of the International Clas-
sification of Diseases, Ninth Revision, Clinical Modifi-
cation (ICD-9-CM). Generally speaking, the first-listed 
diagnosis concerns the main condition identified during 
the patient’s hospital stay, while other diagnoses indi-
cate associated or contributing conditions (comorbidi-
ties and/or complications). 
Inclusion and exclusion criteria
The PRH rate was calculated considering all hospitaliza-
tions identified from the HDRs as having a first-listed di-
agnosis on discharge of bacterial pneumonia potentially 
preventable by vaccination, or a first-listed diagnosis on 
discharge of meningitis, septicemia, or empyema associ-
ated with a secondary diagnosis of bacterial pneumonia 
potentially preventable by vaccination. Table I shows the 
diagnostic codes used as inclusion criteria. Only HDRs 
concerning residents of the Veneto or Friuli Venezia Gi-
ulia regions were considered. Day hospital admissions 
were disregarded for the purpose of this analysis.
Comorbidity
We obtained information on comorbid conditions from 
all hospital diagnoses mentioned in the HDRs. The ICD-
9-CM diagnostic codes were selected on the basis of the 
current recommendations for pneumococcal vaccination 
in the Italian vaccination program  [12] (see Table  II). 
The presence of at least one of these comorbidity codes 
was used to classify patients by specific comorbidities.
Pneumonia-related hospitalization rate 
Based on the total number of hospital admissions con-
cerning Veneto and Friuli Venezia Giulia residents in 
each year considered, annual hospitalization rates were 
calculated by dividing the annual number of hospitaliza-
tions by the population in the year considered, accord-
ing to the Veneto Regional Authority’s statistical office, 
and expressing the rates as hospitalizations per 100,000 
population. For patients readmitted within 30 days, only 
the first hospital stay was considered when calculating 
the hospitalization rate. The length of hospital stays 
was calculated as the days elapsing between the dates 
of admission and discharge, and the mean hospital stay 
was calculated. The case-fatality rate (CFR) was calcu-
lated by dividing the number of in-hospital deaths by 
the number of patients hospitalized with a diagnosis of 
pneumonia-related diseases, expressed as a percentage. 
Only first hospital stays were considered.
Temporal trends of the PRH rate  
by vaccination period
In the Veneto, the vaccination coverage for 24-month-
old infants was low (10-40%) up until 2005, then rapidly 
increased from 2006 to 2010 (70-80%), and has exceed-
ed 80% since 2011. In Friuli Venezia Giulia, the cover-
age rate was low up until 2009, then reached 70-80% in 
2009, and has exceeded 80% since 2010.
Tab. I. Diagnostic codes used for hospital discharge record selection.
Pneumonia-related hospitalization
Discharge Diagnoses Group
International Classification of Diseases 9 – Clinical Modification Codes
First-listed discharge diagnosis
Another discharge 
diagnosis
Pneumococcal pneumonia  
[S. pneumoniae pneumonia]
481
Unspecified pneumonia [pneumonia 
without a causative organism identified]
485-487; 482.9
Meningitis
321, 013.0, 003.21, 036.0, 036.1, 047, 047.0, 047.1, 047.8, 047.9, 
049.1, 053.0, 054.72, 072.1, 091.81, 094.2, 098.82, 100.81, 112.83, 
114.2, 115.01, 115.11, 115.91, 130.0, 320, 320.0, 320.1, 320.2, 
320.3, 320.7, 320.81, 320.82, 320.89, 320.8, 320.9, 322, 322.0, 322.9
plus
481; 485-487; 482.9
Septicemia
038.1, 038.4, 003.1, 020.2, 022.3, 031.2, 036.2, 038, 038.0, 038.2, 
038.3, 038.8, 038.9, 054.5, 790.7
plus
481; 485-487; 482.9
Empyema 510
plus
481; 485-487; 482.9
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In classifying vaccination coverage at 24  months, we 
distinguished between: a “PCV7 period”, when the cov-
erage rate was < 40%; a “late PCV7 period” when it was 
70-80%; and a “PCV13 period”, when it exceeded 80% 
(Tab. III). 
Throughout the study period, the 23-valent pneumococ-
cal polysaccharide vaccine (PPV23) was optionally of-
fered to 65-year-olds, achieving a low coverage (< 50%) 
in both regions.
For each region (considering only first hospital admis-
sions), the trends of the PRH rates were calculated for 
the three vaccination periods and correlated with the 
pneumococcal vaccination coverage in children. 
Estimated cost
The annual cost of the PCV13 vaccination campaign 
was calculated using the acquisition cost of the vaccine 
(€ 42.5 per dose; three doses for children and one dose 
for a one cohort strategy (in the elderly), the time per 
injection for immunization activities (physician, health 
visitor or nurse, records: 8.6 minutes [13]). To convert 
this time into a cost, we considered the hourly cost of 
each actor (€ 71/hour for a physician, € 18 for a health 
visitor). The vaccination coverage rate considered to es-
timate the overall cost was 90% of children and 50% of 
elderly people. The population considered was the resi-
dent population in 2014 (newborn and 65 year-olds).
The estimated cost to the health care system of PRHs 
was calculated using the diagnosis-related groups 
(DRGs) of hospitalized patients. The DRGs depend 
on the patients’ ICD classification at the time of their 
discharge from hospital, their age and gender, and the 
consumption of resources during their hospital stay. Ac-
cording to the DRG-based reimbursement system, every 
hospitalized patient belongs to a group of diagnostically 
homogeneous cases. Patients within each category are 
therefore similar in clinical terms, and are expected to 
require the same level of hospital resources. As a result, 
patients in the same DRG are assigned the same reim-
bursement charges. All hospital stays were considered 
for patients readmitted within 30 days. 
Statistical analysis 
The data were analyzed using the chi-square test, Stu-
dent’s t-test for unpaired data, and Pearson’s test, and 
95% confidence intervals were calculated, as appropri-
ate. A p value < 0.05 was considered significant. Analy-
ses were performed using the Statistical Package for the 
Social Sciences (SPSS 16.0; SPSS Inc., Chicago, IL, 
USA). Significant trends over the years considered were 
assessed as average annual percent changes (AAPC), a 
summary measure of the trend over a given fixed inter-
val that is computed as a weighted average of the an-
nual percent change (APC) emerging from the joinpoint 
model, using weights equating to the length of the APC 
interval. If an AAPC lies entirely within a single join-
point segment, the AAPC is the same as the APC for that 
segment [14]. 
Ethical principles
The study was conducted on data routinely collected by 
the health services and linked to anonymized records that 
make it impossible to identify the individuals concerned. 
The data analysis was performed on anonymized aggre-
gated data in the Local Health Authority registries that 
are recorded with the patient’s consent and can be used 
in aggregate form for scientific studies without further 
authorization [15]. This study complies with the Decla-
ration of Helsinki and with Italian privacy law (Decree 
n. 196/2003 on the protection of personal data).
Results
Pneumonia-related hospitalizations 
Overall, we identified 133,936 PRHs and 8,214 (6.1%) 
of them were disregarded because they concerned re-
admissions within 30 days. Of the 125,722 hospitaliza-
Tab. II. Diagnostic codes considered to identify comorbidities.
Code description
International Classification of Diseases 9 – Clinical 
Modification Codes
Asplenia or severe dysfunction of the spleen 282.5-282.6, 289.4-289.5; 759.0
Chronic renal disease or nephrotic syndrome 581, 582, 584, 585;
Immunodeficiency or immunosuppression 0420-0449, 279
Chronic heart disease 393-398, 414, 416
Chronic lung disease 490-496
Chronic liver disease 571-573
Diabetes mellitus 250
Malignant neoplasms 140-209
Tab. III. Study period and vaccination coverage in children by region.
Vaccine 
Period Vaccination 
coverage in 
children
(24 months 
of age)
Type of 
offerVeneto
Friuli 
Venezia 
Giulia
PCV7 
2004-2005 2004-2008 < 40%
limited to 
groups at 
risk
2006-2010 2009-2010 70-80% extended 
to all 
childrenPCV13 2011-2013 2011-2013 > 80%
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tions thus included in the analysis, 6.8% (8,510 hospi-
talizations) concerned children under five years of age, 
and 75.3% (94,715 hospitalizations) concerned adults 
over 65. The first diagnosis was pneumonia in 121,823 
(96.9%) of cases, while it was pneumonia-related sep-
ticemia in 3,025 (2.4%), meningitis in 539 (0.4%) and 
empyema in 335 (0.3%).
The patients were male in 52.6% of cases (66,131 pa-
tients); the mean hospital stay was 11.9 ± 10.1 days, and 
did not vary between genders. The mean hospital stay 
increased significantly with age (p  <  0.001), reaching 
about 13 days for patients aged 65 or more.
The characteristics of the sample are shown in Table I. 
In the sample as a whole, 32.4% of patients had at least 
one chronic comorbidity and the number of comorbidi-
ties tended to increase with age (p < 0.001); their fre-
quencies by principal type are shown in Figure 1. As for 
outcome, the overall CFR was 12.4% and remained sta-
ble during the study period. This rate increased with age, 
peaking in people over 80 years old (19.6%).
The overall annual PRH rate during the study period was 
204.6 per 100,000 population (221.2 per 100,000 males 
and 188.8 per 100,000 females). Both genders showed 
two age-related peaks, one in children aged 0-4 years 
(325.6 per 100,000 in males, 288.9 per 100,000 in fe-
males), the other in adults over 65 years old (844.9 per 
100,000 in males, 605.7 per 100,000 in females). The 
hospitalization rates for pneumonia were highest for 
the 0-4 and 80+ age groups, irrespective of the differ-
ent types of vaccine used or their coverage. The rates 
for children up to 4 years of age were similar to those 
for 65- to 79-year-olds, at about 330 hospitalizations per 
100,000 population a year. The PRH rate was stable dur-
ing the study period, ranging from 200.9 per 100,000 in 
2004 to 198.7 per 100,000 in 2013 [AAPC: 0.3%; (95% 
CI: -1.0; 1.6)]. The rate dropped significantly among 
the 0- to 4-year-olds, from 379.7 per 100,000 in 2004 
to 211.9 per 100,000 in 2013 [AAPC: -4.6%; (95% CI: 
-6.5; -2.7)], while it rose significantly for adults aged 80 
or more, from 1,370.3 per 100,000 in 2004 to 1,658.4 
per 100,000 in 2013 [AAPC: 2.7%; (95% CI: 1.2; 4.3)] 
(Fig. 2).
Figure 3 shows that the PRH rate was consistent with 
the timing of the vaccination programs by region. The 
PRH rate was 204.9 per 100,000 in the Veneto, and 
203.3 per 100,000 in Friuli Venetia Giulia. In the Veneto, 
the PRH rate dropped for the 0- to 4-year-olds from the 
early PCV7 period (2004-2005) to the late PCV7 period 
(2006-2010), and to the PCV13 period (2011-2013): 
-9.3% and -29.0% respectively; p < 0.01. A significant in-
verse trend was seen for people over 80 years old, whose 
PRH rates rose by 9.9% and 25.2%, respectively, over 
Tab. IV. Hospital admissions for pneumonia by patients’ characteristics and age group (2004-2013).
Variable Total
Age groups
0-4 5-14 15-64 65-79 80 +
Number of subjects 125,722 8,510 3,924 18,573 32,926 61,789
Gender [n (%)]
Males 66,131 (52.6) 4,625 (54.3) 2,167 (55.2) 11,450 (61.6) 20,646 (62.7) 27,243 (44.1)
Females 59,591 (47.4) 3,885 (45.7) 1,757 (44.8) 7,123 (38.4) 12,280 (37.3) 34,546 (55.9)
First-listed diagnosis [n (%)]
Pneumonia 121,823 (96.9) 8,319 (97.8) 3,838 (97.8) 17,600 (94.8) 31,677 (96.2) 60,389 (97.7)
S. pneumoniae 4,002 (3.2) 659 (7.7) 371 (9.5) 967 (5.2) 930 (2.8) 1075 (1.7)
without a causative organism 
identified
117,821 (93.7) 7,660 (90.0) 3,467 (88.4) 16,633 (89.6) 30,747 (93.4) 59,314 (96.0)
Septicemia 3,025 (2.4) 88 (1.0) 28 (0.7) 582 (3.1) 1015 (3.1) 1,312 (2.1)
Meningitis 539 (0.4) 50 (0.6) 16 (0.4) 248 (1.3) 177 (0.5) 48 (0.1)
Empyema 335 (0.3) 53 (0.6) 42 (1.1) 143 (0.8) 57 (0.2) 40 (0.1)
Comorbidity [n (%)]
Chronic lung disease 13,965 (11.1) 307 (3.6) 115 (2.9) 1,255 (6.8) 4,994 (15.2) 7,294 (11.8)
Diabetes mellitus 13,574 (10.8) 1 (0.0) 7 (0.2) 1,494 (8.0) 5,186 (15.8) 6,886 (11.1)
Chronic heart diseases 10,990 (8.7) 10 (0.1) 1 (0.0) 454 (2.4) 3,319 (10.1) 7,206 (11.7)
Malignant neoplasm 7,380 (5.9) 19 (0.2) 26 (0.7) 1,088 (5.9) 3,154 (9.6) 3,093 (5.0)
Chronic liver disease 2,882 (2.3) 9 (0.1) 6 (0.2) 1,000 (5.4) 1,161 (3.5) 706 (1.1)
Immunodeficiency 135 (0.1) 16 (0.2) 10 (0.3) 62 (0.3) 36 (0.1) 11 (0.0)
Asplenia 93 (0.1) 33 (0.4) 31 (0.8) 17 (0.1) 6 (0.0) 6 (0.0)
Chronic renal disease 110 (0.1) 1 (0.0) 5 (0.1) 27 (0.1) 39 (0.1) 38 (0.1)
Length of hospital stay 
[days (DS)]
11.9 (10.1) 4.7 (3.9) 4.9 (3.7) 10.9 (10.3) 13.,0 (10.2) 12.9 (10.2)
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the same periods. In Friuli Venezia Giulia, the figure was 
much the same for the 0- 4-year-olds, with reductions of 
21% and 31.7% from the early to the late PCV7 period, 
to the PCV13 period (p < 0.01); while the PRH rate rose 
by 8.4% (p < 0.01) from the first to the last period among 
individuals aged 80 years or more (Fig. 3).
The overall estimated costs of the vaccination campaign 
for new-born and 65-year-olds was € 8.5 million (€ 6.4 
Fig. 1. Percentage of comorbidity and case fatality rate by type of comorbidity and age group (2004-2013).
Fig. 2. Pneumonia-related hospitalization rate (per 100,000 population) by age group (2004-2013).
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million in children and € 2.1 million in the elderly). The 
purchase of PCV13 vaccine cost € 7.6 million (€ 5.9 for 
children and € 1.7 for the elderly). 
The estimated overall annual cost of the PRHs was ap-
proximately € 41 million, with an estimated cost per pa-
tient of €  3,059. People over 65 accounted for 74.9% 
of the estimated annual overall pneumonia-related cost 
(€ 30.6 million in all, corresponding to € 22.9 per person 
over 65 in the general population). 
Discussion
This retrospective observational study assessed the 
trends of pneumonia-related hospitalization in a popula-
tion of 6.2 million, confirming that the burden on hospi-
tal resources is an important public health issue.
The PRH rate was stable on the whole, but dropped 
significantly for infants (0-4 years old), and this trend 
may be thanks to a greater vaccination coverage in this 
age group since 2008. Hospital admissions for pneumo-
nia involving children aged 0-4 years dropped once the 
PCV7 coverage rate improved, and even more after the 
PCV13 vaccine was introduced. The same situation was 
confirmed in both regions, but Friuli Venezia Giulia had 
a lower hospitalization rate than the Veneto, probably 
due to differences in the two regions’ admission mo-
dalities for this age group. Much the same picture has 
emerged in other areas [9, 10, 16].
The reduction in PRHs for infants seen in our sample 
was initially lower than the figures reported in previ-
ous observational studies  [8,  17]. This may be due to 
a different diffusion of pneumococcal serotypes in our 
region, leading to a better coverage after the addition of 
more serotypes in the 13-valent conjugate vaccine (espe-
cially 19A, 3 and 1) [18]. 
The risk of pneumonia increases considerably with age 
and our analysis revealed a rising trend in the hospitaliza-
tion rate for the very elderly (80 + years old). In contrast 
with our data, a similar retrospective study conducted in 
the US on hospital discharge records for the years 1997 
to 2009 showed a substantial reduction in adult hospital 
admissions for pneumonia [7]. This difference could have 
several explanations. The magnitude of the indirect ef-
fects of vaccine-derived immunity depends on multiple 
influences relating to the transmissibility of the infection, 
the nature of the vaccine-induced immunity, the serotypes 
circulating, the patterns of mixing and transmitting infec-
tions in a given population, the type and schedule of vac-
cine used, the coverage achieved and, more importantly, 
the population’s immunity. The heterogeneity of immu-
nity and the complexity of populations make it difficult to 
draw comparisons  [19, 20]. Active surveillance systems 
for monitoring invasive bacterial diseases show that se-
rotypes not covered by the 7-valent pneumococcal con-
jugate vaccine (such as 19A) play a significant part in the 
burden of pneumonia-related disease [18], suggesting the 
likelihood of a reversal of the herd effect [21]. 
Our analysis confirms the mortality rate reported in oth-
er studies, with a CFR of 12%, and even higher in high-
risk patients [22]. 
The introduction of PCV13 for infants in north-east Italy 
in 2010, and its subsequent use in people over 65 years old, 
can be expected to produce some benefits in years to come. 
A limitation of this retrospective study lies in that it is 
impossible to rule out external factors that might con-
found the apparent effect of vaccination on the age-
specific rates of hospitalization for pneumonia, such as 
changes in patient management or the diagnostic coding 
of pneumonia. Any systematic shift in the management 
of pneumonia is unlikely to have coincided with the in-
troduction of the pneumococcal vaccine, however [8].
A better understanding of the effects of higher-valence 
vaccines could improve the sensitivity of surveillance 
systems and add to our understanding of the potential 
invasiveness of serotypes not included in PCVs (the 
prevalence of their carriage could be compared with 
their prevalence in invasive pneumococcal disease). This 
is an aspect of surveillance that has hitherto been largely 
overlooked. 
Fig. 3. Average annual pneumonia-related hospitalization rates for children by vaccination coverage (CVC), age group and region
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A large trial to ascertain the efficacy of PCV-13 in adults 
> 65 years of age was begun in the Netherlands in 2008. 
The main objective of this trial was to establish the ef-
ficacy of PCV-13 in the prevention of a first episode of 
vaccine-serotype specific CAP (vaccine efficacy 45.6%). 
The study also tested the efficacy of PCV-13 against first 
episodes of non-bacteremic vaccine-serotype-specific 
CAP and vaccine-serotype-specific invasive pneumo-
coccal disease (IPD). The results indicated that PCV-13 
was effective in preventing vaccine-serotype pneumo-
coccal, bacteremic, and non-bacteremic CAP, and vac-
cine-serotype IPD, but not all-cause CAP [23]. 
It is not easy to estimate the morbidity of S. pneumoniae 
diseases due to variable levels of accuracy in reporting 
the cases diagnosed, and to differences in surveillance 
methods and microbiological methods, but HDRs can be 
useful for assessing the cases severe enough to warrant 
hospitalization [14]. 
In our sample, 96.9% of the patients with pneumonia 
were first-listed diagnoses, so their disease was probably 
community-acquired (since hospital-acquired infections 
are not normally recorded as a first diagnosis). Vaccina-
tion can only have an impact on CAP, not on hospital-
acquired pneumonia, because of the different types of 
agent involved. S. pneumoniae is considered the most 
common pathogen responsible for pneumonia, account-
ing for about 24% of all cases [6, 24]. 
One of the difficulties in this setting concerns the avail-
ability of microbiological data and the dubious accuracy 
of the total number of hospital admissions identified as 
being related to S. pneumoniae (SP) due to coding er-
rors in the hospital records. In our dataset, the number 
of SP-specific diagnoses was very low and varied by age 
group. The use of different diagnostic testing procedures 
may have influenced the pattern emerging between the 
diagnostic subgroups. This is the impression that emerg-
es on comparing the percentage of pneumonia cases of 
unspecified etiology in our study (93.7%) with the 55% 
found in a recent study conducted in Australia, where 
cases hospitalized for CAP underwent a standardized, 
detailed assessment for bacterial and viral pathogens [8]. 
A review on the burden of CAP among adults in Europe 
showed that Italy had the lowest rate of identification of 
pneumococcal disease and recommended improvements 
in the diagnostic assays used to detect pneumococcal 
pneumonia with a view to enhancing the detection rate 
and generating a more accurate epidemiological pic-
ture [25]. 
It is important to ensure a good vaccination coverage 
among older people for both influenza and pneumococ-
cal disease. In the latter period of our study, the annual 
influenza vaccination coverage in our elderly population 
dropped from about 75% in 2004 to about 60% in 2013, 
meaning that other measures are needed to prevent pneu-
monia in seniors [26]. 
Continued monitoring and longitudinal analyses are 
warranted to assess the longer-term effects of various 
contributing factors such as serotype replacement, and 
vaccination coverage, as well as catch-up programs. 
This will be particularly important as new pneumococ-
cal conjugate vaccines offering additional serotype pro-
tection are licensed and included in immunization pro-
grams.
From the economic point of view, the implementation 
of PCV13 vaccination in the elderly is justified by the 
cost-effectiveness of this preventive measure. Our es-
timated costs are similar to those indicated in a model 
used in another study conducted in the same geographi-
cal area [27], presumably indicating that the benefits of 
vaccination could be extended to our context.
Conclusions
Prevention remains the most valuable tool to help reduce 
the burden of pneumonia, and vaccination strategies can 
be used for the primary prevention of infection and pos-
sibly to contain this disease in all age groups. The avail-
ability of new-generation pneumococcal conjugate vac-
cines with a broader antigenic spectrum and suitable for 
people of all ages suggests interesting new opportunities 
for improving the control of pneumococcal disease in 
the population as a whole. 
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